* Hanmi to receive upfront payment of 400 mln euros
* Hanmi eligible for up to 3.5 bln euros in sales
* Sanofi to obtain exclusive worldwide licence
(Adds details)
PARIS, Nov 5 (Reuters) - Sanofi SASY.PA signed a licence
deal with Hanmi Pharmaceutical 128940.KS to develop
experimental, long-acting diabetes treatments, the French
drugmaker said on Thursday, in a deal to revive its diabetes
division.
Korea-based Hanmi will receive an upfront payment of 400
million euros ($434 million) and is eligible for up to 3.5
billion euros in development, registration and sales milestones
as well as double-digit royalties on net sales, Sanofi said.
In exchange, Sanofi will obtain an exclusive worldwide
licence to develop and commercialise a series of therapies.
Hanmi will retain an exclusive option to co-commercialise the
products in Korea and China. urn:newsml:reuters.com:*:nHUG7mbBM5
Shares in Sanofi were up 1.1 percent at 92.78 euros at 0905
GMT, outperforming the CAC 40 Index .FCHI .
Nearly 400 million people worldwide have diabetes, with type
2 accounting for more than 90 percent of cases. Without proper
treatment or lifestyle changes those numbers are expected to
grow substantially.
The transaction highlights Sanofi's willingness to boost its
diabetes division, a major profit earner that has been hurt by
growing competition, especially in the United States.
The company, which will unveil a five-year strategic plan on
Friday, surprised investors last week when it said revenues at
the division would keep falling until 2018. urn:newsml:reuters.com:*:nL8N12T0VP
Although he did not refer specifically to the diabetes
business, Sanofi Chief Executive Olivier Brandicourt told
reporters then that company would consider possible
acquisitions, as well as licensing deals, in the coming months.
The agreement announced on Thursday also shows the growing
power of South Korea as a force in drug research.
According to a study of Research and Markets published in
May, the country is seen as one of the leaders in research and
development in the Asia Pacific region thanks to the strong
involvement of public and private sectors.
($1 = 0.9225 euros)
(Reporting by Matthias Blamont; additional reporting by James
Regan; editing by David Clarke)
((james.regan@thomsonreuters.com; +33)(0)(1 49 49 53 84;
Reuters Messaging: james.regan.thomsonreuters.com@reuters.net))
Keywords: SANOFI HANMI/DIABETES